sanofi_hq__boetie_hall

Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office

pharmafile | April 13, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, Stevenage Bioscience Catalyst, academia, industry, partnership, pharma, stevenage 

Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new partnering office. This office will foster engagement and collaboration between the French pharma company and the network of bioscience companies and academia that form a part of the UK’s vibrant life sciences ecosystem.

Stevenage Bioscience Catalyst was opened as the UK’s first open innovation biomedical campus in 2012 and combines infrastructure and virtual networks to drive collaboration. With the first phase of their plan completed, its second stage will focus on open innovation and convergent medical technologies.

These aims dovetail well with Sanofi’s plan to work with global partners to develop high quality scientific research in areas of unmet need, such as diabetes, oncology, multiple sclerosis and infectious diseases.

Yvonne Naughton, head of external science and partnering at Sanofi UK & Ireland, says: “At Sanofi we recognise that the next big discovery may come from outside of our own laboratories. Core to our strategy is to build strong relationships with biotechnology organisations, research institutes and academic centres.”

Martino Picardo, CEO of Stevenage Bioscience Catalyst, comments: “Sanofi is a fantastic addition to the thriving ecosystem developing here, and we are delighted that it recognises the value of being part of our innovation-focused community. With Sanofi’s focus on transformative new medicines and openness to external innovation, there is a strong strategic fit with SBC and we anticipate a long and fruitful relationship.”

Sean Murray

Related Content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …

Allumiqs and Prolytix enter partnership for acceleration of drug discovery and development

Allumiqs and Prolytix have announced that they have entered into a long-term, strategic partnership with …

Sanofi shares phase 2b results for dermatitis treatment

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …

Latest content